Trauma Prevalence and Its Association With Health-related Quality of Life in Pregnant Persons With Opioid Use Disorder

T. John Winhusen, Frankie Kropp, Shelly F. Greenfield, Elizabeth E. Krans, Daniel Lewis, Peter R. Martin, Adam J. Gordon, Todd H. Davies, Elisha M. Wachman, Antoine Douaihy, Kea Parker, Xie Xin, Ali Jalali, Michelle R. Lofwall

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Objectives Trauma screening is recommended for pregnant persons with opioid use disorder (OUD), but there is limited literature on screening results from buprenorphine treatment. This study's objectives were to 1) describe the types, and severity, of traumatic events reported and 2) evaluate the associations between trauma and health-related quality of life (HRQoL). Methods Baseline data from an ongoing trial were analyzed. Participants were 155 pregnant persons with OUD receiving, or enrolling in, buprenorphine treatment at one of 13 sites. The experience, and relative severity, of 14 high magnitude stressors were assessed with the trauma history screen. The Patient-Reported Outcomes Measurement Information System-29+2 was used to assess 8 HRQoL domains. Results Traumatic stressors were reported by 91% of the sample (n = 155), with 54.8% reporting a lifetime persisting posttraumatic distress (PPD) event and 29.7% reporting a childhood PPD event. The most prevalent lifetime PPD event was sudden death of a close family/friend (25.8%); physical abuse was the most prevalent childhood PPD event (10.3%). Participants with lifetime PPD, relative to no PPD, reported significantly greater pain interference (P = 0.02). Participants with childhood PPD, relative to no PPD, had significantly worse HRQoL overall (P = 0.01), and worse pain intensity (P = 0.002), anxiety (P = 0.003), depression (P = 0.007), fatigue (P = 0.002), and pain interference (P < 0.001). Conclusions A majority of pregnant persons enrolled/enrolling in buprenorphine treatment reported persisting posttraumatic distress with sudden death of close family/friend being the most prevalent originating event; clinicians should consider the impact that the opioid-overdose epidemic may be having in increasing trauma exposure in patients with OUD.

Original languageEnglish
Pages (from-to)20-25
Number of pages6
JournalJournal of Addiction Medicine
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2025

Bibliographical note

Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.

Funding

Sources of support: This work was supported by the National Institute of Health through the NIH HEAL Initiative under award numbers UG1DA013732 to the University of Cincinnati (T. John Winhusen), UG1DA049444 (Adam Gordon and Gerald Cochran), UG1DA015831 (Roger Weiss and Gail D\u2019Onofrio), UG1DA013727 (Kathleen Brady and Matthew Carpenter), UG1DA049468 (Kimberly Page), UG1DA015815 (Keith Humphreys and Todd Korthuis), UG1DA013720 (Jose Szapocznik, Daniel Feaster, and Lisa Metsch), UG1DA049436 (Jane Liebschutz and Judith Feinberg), and UG1DA013714 (John Roll and Mary Hatch-Maillette). The work was also supported by NIDA contracts to the CCC (HHSN271201500065C) and DSC (HHSN271201400028C). The Publications Committee of the National Drug Abuse Treatment Clinical Trials Network reviewed and gave approval for submission of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or its NIH HEAL Initiative. This work was supported by the National Institute of Health through the NIH HEAL Initiative under award numbers UG1DA013732 to the University of Cincinnati (T. John Winhusen), UG1DA049444 (Adam Gordon and Gerald Cochran), UG1DA015831 (Roger Weiss and Gail D'Onofrio), UG1DA013727 (Kathleen Brady and Matthew Carpenter), UG1DA049468 (Kimberly Page), UG1DA015815 (Keith Humphreys and Todd Korthuis), UG1DA013720 (Jose Szapocznik, Daniel Feaster, and Lisa Metsch), UG1DA049436 (Jane Liebschutz and Judith Feinberg), and UG1DA013714 (John Roll and Mary Hatch-Maillette). The work was also supported by NIDA contracts to the CCC (HHSN271201500065C) and DSC (HHSN271201400028C). The Publications Committee of the National Drug Abuse Treatment Clinical Trials Network reviewed and gave approval for submission of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or its NIH HEAL Initiative.

FundersFunder number
John Roll and Mary Hatch-Maillette
Author National Institute on Drug Abuse DA031791 Mark J Ferris National Institute on Drug Abuse DA006634 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA026117 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA028162 Elizabeth G Pitts National Institute of General Medical Sciences GM102773 Elizabeth G Pitts Peter McManus Charitable Trust Mark J Ferris National Institute on Drug Abuse
National Drug Abuse Treatment
University of Cincinnati University Research CouncilUG1DA013720, UG1DA049468, UG1DA015831, UG1DA049436, UG1DA049444, UG1DA013727, UG1DA013714, UG1DA015815
University of Cincinnati University Research Council
National Institutes of Health (NIH)UG1DA013732
National Institutes of Health (NIH)
Direktion für Entwicklung und ZusammenarbeitHHSN271201400028C
Direktion für Entwicklung und Zusammenarbeit
Christian College ConsortiumHHSN271201500065C
Christian College Consortium

    Keywords

    • buprenorphine
    • opioid use disorder
    • pregnant
    • quality of life
    • trauma

    ASJC Scopus subject areas

    • Psychiatry and Mental health
    • Pharmacology (medical)

    Fingerprint

    Dive into the research topics of 'Trauma Prevalence and Its Association With Health-related Quality of Life in Pregnant Persons With Opioid Use Disorder'. Together they form a unique fingerprint.

    Cite this